1. Resin and Molded Plastic Components
Not in registry
Source Explicitly mentioned as ~5% of COGS and byproduct of oil.
Confidence: high
BDX
T2S&P 500Health Care (XLV)Value (IWD)Becton, Dickinson and Company
Loading chart…
OverviewBecton, Dickinson and Company (BDX) is a global medical technology firm providing essential supplies and devices. Its segments—Medical Essentials (34%), Interve
Becton, Dickinson and Company (BDX) is a global medical technology firm providing essential supplies and devices. Its segments—Medical Essentials (34%), Interventional (28%), Connected Care (24%), and BioPharma Systems (13%)—offer solutions for medication management, surgical procedures, patient monitoring, and drug delivery. BD serves healthcare providers, researchers, and pharmaceutical companies worldwide.
Key Inputs And Sourcing
2. Crude Oil
Not in registry
Source Direct input for resin and molded plastic components.
Confidence: high
3. Manufacturing Labor
Not in registry
Source 'approximately 8% gross productivity in our plants'. Extensive manufacturing footprint across multiple countries.
Confidence: high
4. Logistics (Freight & Shipping)
Not in registry
Source Mentioned as an inflationary pressure in transcript. Global supply chain.
Confidence: high
5. Metals (e.g., Steel, Aluminum)
Not in registry
Source Explicit mention of 'American-made steel' for needles. Used in various medical devices and instruments.
Confidence: high
6. Glass
Not in registry
Source Investments in 'BD Neopak™ Glass Prefillable Syringe production'. World's largest manufacturer of BD Vacutainer® tubes.
Confidence: high
7. Specialized Chemicals and Reagents
Not in registry
Source BD Life Sciences segment focuses on diagnostic and research tools. GLP-1 manufacturing involves 'high-purity raw materials' and 'strong, often hazardous chemicals'.
Confidence: medium
8. Electronic Components (e.g., microprocessors, sensors)
Not in registry
Source Used in Alaris pumps, advanced patient monitoring, and pharmacy automation. 'Microprocessor' mentioned as a deep-tier supply chain issue.
Confidence: medium
9. Packaging Materials (e.g., paper, plastic films)
Not in registry
Source Essential for medical device delivery and protection. Mentioned in procurement context.
Confidence: medium
10. Energy (Electricity, Natural Gas)
Not in registry
Source Implied by extensive manufacturing operations across numerous global facilities.
Confidence: medium
Industry Publications
- MD+DI (Medical Device and Diagnostic Industry) (mddionline.com) — Provides news and analysis for medical device developers and manufacturers, covering design, quality, and regulatory topics relevant to BD's diverse product portfolio.
- MedTech Dive (medtechdive.com) — Offers daily coverage of medical device companies, funding, regulatory developments, and innovation across the medtech sector, crucial for monitoring BD's competitive landscape and strategic moves.
- Fierce Medtech (fiercebiotech.com/medtech) — Covers medical device business, R&D, regulatory pathways, and M&A across the medtech sector, providing insights into BD's market and competitive environment.
- GenomeWeb (genomeweb.com) — Offers in-depth reporting on next-generation sequencing, molecular diagnostics assays, and biomarker discovery, which is relevant to BD's diagnostic and life sciences segments.
- Medical Product Outsourcing (MPO) (medicalproductoutsourcing.com) — Focuses on the medical device outsource manufacturing trend, covering feature articles, industry news, and developments pertinent to contract manufacturer-OEM relationships, which is relevant to BD's global supply chain and manufacturing strategies.
Economic Data Watch
1. FRED — National Health Expenditure Accounts (NHEA)
Matchedfred · access=api · map_only
Cadence monthly
Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting the addressable market for BD's products and services.
Signal to watch Increasing total health expenditures is bullish.
Confidence: low
2. FRED — Industrial Production and Capacity Utilization
Matchedfred · access=api · map_only
Metric/field IPMAN
Cadence monthly
Why it matters Reflects the health of the manufacturing sector, which impacts BD's production capabilities, supply chain efficiency, and overall operational costs.
Signal to watch Increasing industrial production in manufacturing is bullish.
Confidence: high
3. BLS — Producer Price Index by Industry
Not in registryaccess=api
Metric/field WPU0611
Cadence monthly
Why it matters Directly tracks input costs for oil-based resins and molded plastic components, which are significant materials for BD's products, impacting gross margins.
Signal to watch Decreasing PPI for plastics material and resin manufacturing is bullish.
Confidence: high
4. Trading Economics — China Industrial Production
Not in registryaccess=scrape
Metric/field China Industrial Production
Cadence monthly
Why it matters Indicates economic activity and demand in China, which, despite being a smaller portion of BD's revenue, remains a key international market and potential sourcing region.
Signal to watch Increasing industrial production in China is bullish.
Confidence: high
5. Trading Economics — Brazil Industrial Production
Not in registryaccess=scrape
Metric/field Brazil Industrial Production
Cadence monthly
Why it matters Reflects economic health and demand in Brazil, a growing market where BD has a new collaboration for semaglutide therapy utilizing its Vystra injection pen.
Signal to watch Increasing industrial production in Brazil is bullish.
Confidence: high
Free Alt Data Watch
1. ClinicalTrials.gov — Clinical Trial Registry
Not in registry
Metric/field Study Status for BD-sponsored trials in 'Advanced Tissue Regeneration'
Cadence event_driven
Why it matters BD has 'quite a few clinical trials underway for new applications' in advanced tissue regeneration, and progress in these trials can lead to new product approvals and market expansion.
Signal to watch Advancement to later phases or positive trial outcomes are bullish.
Confidence: high
2. FDA — Medical Device 510(k) Clearances / PMA Approvals
Not in registry
Metric/field Decision Date and Product Code for Becton, Dickinson and Company
Cadence daily
Why it matters BD regularly launches new medical devices, and new clearances/approvals indicate pipeline success and potential for new revenue streams, such as the Liverty TIPS Stent Graft and Elyra Thulium Fiber Laser System.
Signal to watch Increased number of clearances/approvals is bullish.
Confidence: high
3. Google Trends — Search Interest
Not in registry
Metric/field Search term volume for 'PureWick'
Cadence weekly
Why it matters PureWick is a key growth platform for BD, with new products launching and ongoing efforts for at-home reimbursement, making public and patient interest a relevant indicator.
Signal to watch Increasing search interest is bullish.
Confidence: medium
4. USASpending.gov — Federal Contract Awards
Not in registryaccess=api
Metric/field Award Amount for Becton, Dickinson and Company (BDX) with 'PureWick' keyword
Cadence daily
Why it matters BD has made 'incremental investments in the VA channel for PureWick' and federal contracts represent a direct revenue source, especially for government healthcare channels.
Signal to watch Increasing award amounts or new contracts are bullish.
Confidence: high
5. SEC EDGAR — Form 8-K Filings
Not in registry
Metric/field Full-text search for 'GLP-1 agreement' or 'Vystra pen' in BDX filings
Cadence event_driven
Why it matters BD has signed approximately 100 agreements across novel and biosimilar GLP-1 programs and launched the Vystra injection pen, making new announcements in this area significant for growth.
Signal to watch Announcements of new GLP-1 agreements or product launches are bullish.
Confidence: high
Paid Alt Data Watch
1. IQVIA — Medical Claims Data
Matchediqvia_medical_claims · access=file · map_only
Metric/field CPT code utilization for BD's key product categories (e.g., advanced patient monitoring, peripheral vascular disease, specimen management)
Cadence monthly
Why it matters Provides granular, independent data on actual test and procedure utilization, market share, and reimbursement trends for BD's diverse product portfolio, including areas like advanced patient monitoring and specimen management.
Signal to watch Increasing utilization and market share for BD's products are bullish.
Confidence: high
2. YipitData — Medtech Product Tracks
Matchedyipitdata_hospital_purchasing_medtech_procurement · access=file · map_only
Metric/field Hospital/surgical-center purchasing data for Alaris pumps and consumables
Cadence monthly
Why it matters BD is seeing 'continued share gains in Alaris' and strong infusion set performance, making hospital purchasing data crucial for tracking market penetration and sales momentum.
Signal to watch Increasing purchasing volume and market share for Alaris products are bullish.
Confidence: high
3. Consumer Edge — Healthcare Facilities Procurement Data (Taurus)
Matched (medium)consumer_edge_hospital_purchasing_procurement · access=file · map_only
Metric/field Procurement spend and volume for BD's vascular access management and specimen management portfolios
Cadence monthly
Why it matters BD reported 'strong U.S. performance in MDS and specimen management, driven by broad underlying utilization as well as share gains,' making procurement data a direct measure of demand.
Signal to watch Increasing procurement spend and volume for BD's products are bullish.
Confidence: high
4. Komodo Health — Healthcare Map
Matched (medium)iqvia_patient_flows_longitudinal_healthcare · access=file · map_only
Metric/field Patient journeys and treatment patterns involving BD's interventional products (e.g., peripheral vascular disease, advanced tissue regeneration)
Cadence monthly
Why it matters BD's Interventional segment is a key growth driver, with strong performance in peripheral vascular disease and advanced tissue regeneration, making patient treatment patterns a valuable indicator of market adoption.
Signal to watch Increasing patient engagement with BD's interventional therapies is bullish.
Confidence: high
5. Definitive Healthcare — PhysicianView
Not in registry
Metric/field Physician prescribing and usage patterns for BD's drug delivery systems (e.g., GLP-1 related biologics)
Cadence monthly
Why it matters BD is seeing 'continued double-digit growth in biologics, led by GLP-1s,' and tracking physician adoption of its drug delivery systems is crucial for understanding market penetration.
Signal to watch Increasing physician adoption and usage of BD's drug delivery systems are bullish.
Confidence: high
Search Keywords Brand Product
- PureWick
- Alaris infusion pump
- HemoSphere Alta
- Liverty TIPS Stent Graft
- Elyra Thulium Fiber Laser System
- Acumen IQ Plus Finger Cuff
- BD Vacutainer
- Rowa Pharmacy Automation
- Vystra injection pen
- Pyxis Pro
- BD Incada
- medical technology
- medtech innovation
- biologic drug delivery
- advanced patient monitoring
- pharmacy automation
- peripheral vascular disease
- advanced tissue regeneration
- infection prevention
- surgical solutions
- hospital utilization
- GLP-1 programs
Search Keywords Event Phrases
- BD earnings
- BD Investor Day
Search Keywords Policy Regulatory
- Alaris remediation
- tariffs
- What They Do (Plain English & Analogies)
- BD (Becton, Dickinson and Company) is like a comprehensive toolkit for hospitals and healthcare providers worldwide. They make a vast array of essential medical products, from everyday items like syringes and needles for giving shots, to advanced equipment for surgery, patient monitoring, and diagnosing diseases. Think of them as providing much of the 'plumbing' and 'instrumentation' that keeps a hospital running, helping doctors and nurses deliver care, manage medications, and perform tests. They also create specialized systems for drug delivery, including those for new powerful medicines like GLP-1s, and automation solutions for pharmacies. Following the spin-off of its Life Sciences business, BD is now a more focused medical technology company, concentrating on medication management, interventional procedures, connected care solutions, and biopharmaceutical systems.
- Very Brief History
- Founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson, Becton, Dickinson and Company later moved its headquarters to Franklin Lakes, New Jersey. Over its long history, BD has grown into a global medical technology leader through continuous innovation and strategic acquisitions, such as CareFusion in 2014 and C. R. Bard in 2017. In recent years, the company has undergone significant portfolio reshaping, including the spin-off of its diabetes care business (Embecta Corporation) in 2022 and its Biosciences & Diagnostic Solutions business (in combination with Waters Corporation) in February 2026, to become a more focused 'New BD' medical technology company.
- "Street Stereotype"
- The 'Street stereotype' for BDX has historically been that of a large, diversified medical conglomerate with a massive corporate footprint in traditional hospital hardware like syringes and catheters. While recognized for its solid molecular diagnostics arm, this was often seen as diluted by its broader portfolio, leading to a perception that it lacked the explosive upside and pure-play exposure of more specialized early-detection or diagnostics companies. However, with the recent spin-off of its Life Sciences business, the company is actively working to redefine itself as a more focused med tech company, aiming to demonstrate enhanced growth and earnings potential.
- Subsidiaries On Linked In*
- BD Medical — Division focused on medication management and delivery; LinkedIn: BD Medical
- BD Interventional — Division focused on minimally invasive surgical and interventional procedures; LinkedIn: BD Interventional
- Rowa Technologies — Brand/entity focused on pharmacy automation, acquired by BD; LinkedIn: Rowa Technologies
- Customer Sectors & Example Clients
- BD's customers span a wide range of healthcare sectors, including healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public. Specific client types mentioned or implied include hospitals (operating rooms, intensive care units), government healthcare channels (e.g., the Veterans Administration for PureWick products), and pharmaceutical companies. An example client mentioned is EMS, one of Brazil's leading pharmaceutical companies, with whom BD has a collaboration for GLP-1 therapies. Based on their business model, other likely clients would include major hospital networks (e.g., HCA Healthcare, Mayo Clinic), large pharmaceutical manufacturers, and independent clinical laboratories.
- New Customers / Segments They'Re Targeting
- BD is actively targeting new customer segments and expanding its reach. This includes underserved operating room (OR) and intensive care unit (ICU) patients with advancements in noninvasive monitoring, such as the Acumen IQ Plus Finger Cuff and Smart Pressure Controller. The company is also in the early stages of seeking reimbursement for at-home use of its PureWick product, indicating a strategic push into the home care setting. Furthermore, BD is expanding its partnerships with pharmaceutical companies for biologic drug delivery, particularly in the rapidly growing GLP-1 market, having signed approximately 100 agreements across novel and biosimilar GLP-1 programs.
- Sales Geographies And Expansion Plans
- BD sells its products globally, serving customers around the world. The company reported strong performance in the U.S. across its Medical Essentials and Connected Care portfolios. While facing continued pressure in China, this market now represents a much smaller portion of BD's revenue, expected to drop to 3-4% of New BD revenue next year. BD is actively expanding its sales presence, as evidenced by the early European launch of the differentiated Liverty TIPS Stent Graft and the commercial availability of new noninvasive monitoring technologies in both the U.S. and Europe. They also announced a new collaboration with EMS in Brazil for a semaglutide therapy utilizing their Vystra injection pen, indicating expansion in Latin American healthcare markets. Efforts to secure reimbursement for at-home use of PureWick suggest plans to expand into home care settings within existing geographies.
- How Key Themes May Help/Hurt
- BD's exposure to the 'MedTech Long '26: Diagnostics & Early Detection' theme is somewhat diluted due to its broad portfolio, which historically lacked the 'pure-play exposure' of more specialized diagnostic companies. However, the company's specimen management business, which includes products like BD Vacutainer, delivered high single-digit growth driven by share gains and improved supply, indicating strong performance in a diagnostic-related area. An observed uptick in tube utilization versus needle utilization suggests more diagnostic testing per patient, which could benefit BD's diagnostic-related product lines. The company's investment in AI for its supply chain could also indirectly support diagnostic operations by improving efficiency. Regarding the 'GLP-1 Long '24: GLP1 Equip/Distrib' theme, BD is well-positioned to benefit significantly. The company reported continued double-digit growth in biologics, led by GLP-1s, and has approximately 100 agreements signed across novel and biosimilar GLP-1 programs. The launch of a semaglutide therapy utilizing BD's Vystra injection pen represents a higher value capture, indicating a strong leverage of the increasing demand for GLP-1 drugs. The 'TrumpPolicy PreElection Long '24: Tariff Winners' theme presents a mixed impact. While BD's adjusted operating margins were offset by approximately 110 basis points of tariff impact in the recent quarter, the company is taking proactive pricing actions and leveraging its operational efficiencies through BD Excellence to mitigate these costs. If trade policies continue to favor domestic manufacturing or if BD can effectively pass on tariff-related costs, it could partially offset the negative impact, but tariffs remain a headwind.
3 Main Long-Term Bull Details
- Growth Platform Momentum and Innovation: BD is experiencing strong, broad-based growth across its key platforms, including biologic drug delivery (especially GLP-1s), advanced patient monitoring, PureWick, advanced tissue regeneration, peripheral vascular disease, and Rowa pharmacy automation. The company is actively investing in and launching innovative products within these high-growth areas, such as the Liverty TIPS Stent Graft and the Elyra Thulium Fiber Laser System, which are expected to fuel sustained revenue acceleration.
- Operational Excellence and Margin Expansion: The 'BD Excellence' operating system is consistently driving significant productivity gains (approximately 8% gross productivity in plants quarterly) and improving gross and operating margins through plant consolidations, raw material savings, waste reduction, and higher efficiencies. The ongoing investment in AI for the supply chain and G&A functions is anticipated to provide further meaningful runways for productivity and service improvement, contributing to long-term margin expansion.
- Strategic Focus as 'New BD' and Capital Allocation: Following the spin-off of its Life Sciences business, BD is operating as a more focused med tech company. This strategic clarity allows for disproportionate reallocation of R&D and commercial investments into the highest-growth sectors, enhancing customer partnerships and driving sustainable share gains. The company's disciplined capital allocation framework, including share repurchases and selective high-growth tuck-in M&A, is supported by improving free cash flow, providing firepower for future growth.
3 Main Long-Term Bear Details
- Lingering Headwinds and Transitionary Pressures: BD faces defined headwinds from the Alaris remediation, which is expected to create a 200 basis point revenue headwind in fiscal year 2027, and ongoing pressure from vaccines in China. While these are expected to be temporary, they will continue to impact top-line growth in the near to medium term, requiring strong performance from other segments to offset the impact.
- Macroeconomic and Geopolitical Volatility: The company is exposed to dynamic macroeconomic environments, including potential inflation impacting input costs (such as oil-based resins for plastics) and geopolitical factors like tariffs, which have already impacted operating margins (110 basis points in Q3 2026). While BD is taking proactive pricing actions, sustained or escalating cost pressures could challenge profitability.
- Intense Competition and Need for Continuous Innovation: Operating in a highly competitive medical technology market, BD must continuously innovate and execute commercially to maintain and gain market share. Competitors are active across its segments, and the company's ability to consistently deliver breakthrough products and maintain strong commercial execution will be critical to offsetting competitive pressures and ensuring long-term growth.
- Competitors And Differentiation
- BD operates in a highly competitive medical technology market. While specific competitors are not named in the transcript, BD's differentiation strategy focuses on commercial excellence, product innovation, and operational efficiency. The company aims to convert the strength of its portfolio into faster growth, deeper customer partnerships, and sustainable share gains. They are achieving high win rates across the biologics market, including GLP-1s. BD's scale, combined with its 'BD Excellence' operating system embedded across its manufacturing network, is considered a growing competitive advantage, translating into efficiency, resiliency, and consistency for its customers. The company also highlights its focused innovation model, launching differentiated products like the Liverty TIPS Stent Graft, which enters a market with limited prior innovation, and the Elyra Thulium Fiber Laser System, which plays to BD's strengths in disposables within the endourology market.
- Recent Performance & What The Market'S Focused On
- BD delivered a strong third fiscal quarter of 2026, surpassing expectations with revenue of $5 billion (up 4.4% FX-neutral), adjusted operating margin of 24.9%, and adjusted EPS of $3.23 (up 4.9%). This performance was broad-based, with over 90% of its portfolio delivering high single-digit growth and several key platforms achieving double-digit expansion. The company raised its full-year fiscal 2026 guidance, now expecting revenue growth toward the high end of its low single-digit range and raising the midpoint of its adjusted EPS guidance to $12.62 to $12.72. The market is focused on BD's ability to sustain the momentum in its growth platforms, effectively mitigate the anticipated 200 basis point Alaris revenue headwind in fiscal 2027, and continue driving margin expansion through BD Excellence and AI deployment initiatives, while navigating persistent tariff impacts and potential inflationary pressures.
- Revenue Segments And Estimated Mix
- Medical Essentials — Mix: 34%; Source: Ticker_Overview, Q3 2026 earnings transcript; Trend: Grew 3.2% in Q3 2026, with strong U.S. performance in MDS and specimen management, partially offset by China pressure.
- Connected Care — Mix: 24%; Source: Ticker_Overview, Q3 2026 earnings transcript; Trend: Grew 4.4% in Q3 2026, led by double-digit growth in advanced patient monitoring and low single-digit growth in MMS, partially offset by difficult prior year comparison in Alaris capital.
- BioPharma Systems — Mix: 13%; Source: Ticker_Overview, Q3 2026 earnings transcript; Trend: Grew 5.2% in Q3 2026, driven by continued double-digit growth in biologics (led by GLP-1s), partially offset by lower demand for vaccine products. Excluding vaccines, grew mid-teens.
- Interventional — Mix: 28%; Source: Ticker_Overview, Q3 2026 earnings transcript; Trend: Grew 5.5% in Q3 2026, with solid mid-single-digit growth across the segment, led by PI (oncology, peripheral vascular disease), UCC (PureWick), and Surgery (infection prevention, advanced tissue regeneration).
- Product Brands
- PureWick
- Alaris
- HemoSphere Alta
- Smart Recovery
- Liverty TIPS Stent Graft
- Elyra Thulium Fiber Laser System
- Acumen IQ Plus Finger Cuff
- Smart Pressure Controller
- BD Vacutainer
- Rowa Pharmacy Automation
- Vystra injection pen
- Pyxis Pro
- BD Incada
- 3DMax
- AccuCath Ace
- AllPoints
- Arctic Sun
- ArcticGel
- Arista
- Aspirex
- Atlas
- Avitene
- BBS Revolution
- BD Affirm
- BD Angiocath
- BD Aptra
- BD BACTEC
- BD BBL
- BD COR
- BD Cathena
- BD CentroVena One
- BD CentroVena
- BD ChloraPrep
- BD CultureSwab
- BD CytoRich
- BD Difco
- BD E-Z Scrub
- BD Eclipse
- BD EleVation
- BD Epilor
- BD Falcon
- BD FecalSwab
- BD FocalPoint
- BD GasPak
- BD HealthSight
- BD Hycheck
- BD Insyte-N
- BD Insyte-W
- BD Insyte
- BD Insyte Autoguard
- BD Intramedic
- BD Introsyte
- BD Lactinex
- BD MAX
- BD MGIT
Bull / Bear DetailsBecton, Dickinson and Company (BDX) demonstrates robust execution and strategic focus post-spin-off, achieving broad-based growth across key platforms like biol
Thesis
Becton, Dickinson and Company (BDX) demonstrates robust execution and strategic focus post-spin-off, achieving broad-based growth across key platforms like biologic drug delivery and advanced patient monitoring. Operational excellence via BD Excellence and targeted innovation are fueling margin expansion and market share gains. While defined Alaris, China, and vaccine headwinds persist, their contained nature and the company's strong pipeline position BDX for sustained performance and modest EPS leverage in FY27, with long-term growth potential. (Updated: 2026-10-25)
Bull case
BD's 'New BD' strategy is yielding strong, broad-based growth, with Q3 2026 revenue up 4.4% and over 90% of its portfolio delivering high single-digit growth. Key platforms like biologic drug delivery (including 100 GLP-1 agreements), advanced patient monitoring, and PureWick are achieving double-digit expansion, driven by effective commercial investments that directly translate into market share gains.
Operational excellence through BD Excellence continues to drive significant productivity gains, with approximately 8% gross productivity improvements in plants quarterly. Strategic investments in AI for the end-to-end supply chain and G&A functions are expected to further enhance efficiencies, improve cash flow, and contribute to sustained operating margin expansion, effectively mitigating external cost pressures like tariffs.
BD is strategically innovating and expanding its presence in attractive, high-growth markets. Recent product launches, such as the Liverty TIPS Stent Graft in the $2 billion global venous market and the Elyra Thulium Fiber Laser System in the $1.5 billion endourology market, along with advancements in noninvasive monitoring, demonstrate a focused pipeline designed to strengthen long-term growth.
Bear case
The Alaris remediation remains a significant, albeit defined, headwind, projected to create a 200 basis point drag on revenue growth in fiscal year 2027. This, coupled with ongoing pressure from vaccine demand and China market dynamics (now a smaller portion of revenue), concentrates headwinds on a portion of the portfolio, requiring strong performance from other segments to offset the impact.
Tariffs continue to exert pressure on profitability, evidenced by a 110 basis point impact on adjusted operating margin in Q3 2026. While BD is implementing pricing actions, persistent inflation in input costs, particularly for oil-based resins and freight, could continue to challenge gross and operating margins, necessitating continuous and effective productivity offsets.
Despite strong reported share gains in certain areas, the medical technology market is intensely competitive across BD's diverse segments. Furthermore, the broader diagnostics and medical device industry faces persistent reimbursement pressures and evolving payer policies, which could impact the market uptake and profitability of both existing and newly launched products, particularly in areas requiring novel coverage.
Bull / Bear Case
- Bear Case
- BDX faces significant, albeit defined, near-term headwinds, primarily the Alaris remediation, which is projected to create a 200 basis point drag on revenue growth in fiscal year 2027. This is compounded by ongoing pressure from vaccine demand and dynamic China market conditions, concentrating risks on a portion of the portfolio. Profitability continues to be impacted by external factors, as seen with a 110 basis point tariff impact on adjusted operating margin in Q3 2026. Persistent inflation in input costs, particularly for oil-based resins and freight, could further challenge gross and operating margins despite pricing actions. The intensely competitive medical technology market, coupled with evolving reimbursement pressures, poses ongoing risks to the market uptake and profitability of both existing and newly launched products.
- Bull Case
- Becton, Dickinson and Company (BDX) is demonstrating robust execution of its 'New BD' strategy, evidenced by strong Q3 2026 revenue growth of 4.4%, with over 90% of its portfolio delivering high single-digit expansion. Key growth platforms like biologic drug delivery (including 100 GLP-1 agreements), advanced patient monitoring, and PureWick are achieving double-digit growth, fueled by targeted commercial investments and strategic innovation. Operational excellence through 'BD Excellence' continues to drive significant productivity gains (approximately 8% gross productivity quarterly) and margin expansion, further enhanced by investments in AI for supply chain and G&A functions. The company's focused pipeline, with new launches in high-growth markets such as the $2 billion global venous market and $1.5 billion endourology market, positions BDX for sustained long-term growth and improved profitability.
- More Compelling & Why
- Bull. The Alaris headwind, while significant, is clearly defined and temporary, expected to resolve after FY27. This temporary drag, combined with strong underlying double-digit growth in key platforms like GLP-1 related biologics and Advanced Patient Monitoring, and consistent operational excellence through BD Excellence, suggests the market may be undervaluing the company's post-FY27 growth acceleration. If BDX is currently trading at a forward P/E of 23x, which is slightly below its historical average and peer group, it presents an attractive entry point. My view would flip if the Alaris remediation extends beyond FY27 or if the growth in key platforms significantly decelerates, indicating weaker underlying business momentum.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Alaris Remediation Headwind Resolution | The Alaris remediation has been a significant, quantified drag on BD's revenue growth. Its full resolution will remove a substantial headwind, allowing the company's underlying growth to become more apparent and accelerating overall revenue performance. | Management's explicit confirmation in future earnings calls, particularly the FY27 guidance in November 2026, that the 200 basis point revenue headwind from Alaris has been fully removed. | Bullish if the 200 basis point revenue headwind from Alaris is confirmed to be fully removed in FY27, leading to an acceleration of overall revenue growth towards BD's mid-single-digit algorithm. | Company earnings calls, press releases, and SEC filings (10-K, 10-Q), specifically the FY27 guidance call in November 2026. | [] | [] |
| Growth Platform Performance & Commercial Execution | BD's strategy focuses on accelerating growth in key platforms through innovation and targeted commercial investments. Sustained double-digit growth and market share gains in these areas are critical for overall revenue acceleration and favorable mix. | Specific revenue contributions or market share gains from newly launched products (Liverty TIPS Stent Graft, Elyra Thulium Fiber Laser System, Acumen IQ Plus Finger Cuff), continued double-digit growth in platforms like Advanced Patient Monitoring (APM) and PureWick, and quantifiable impact of commercial investments (e.g., 100-150 bps to APM growth). | Bullish if new product launches are cited as material contributors to segment growth or market share gains, and if key growth platforms like APM and PureWick maintain double-digit growth rates, with commercial investments yielding stated benefits. | Company earnings calls, press releases, investor presentations, and product launch announcements. | 1. ClinicalTrials.gov — Clinical Trial RegistryNot in registry Metric/field New clinical trials for advanced tissue regeneration applications (NCT ID) Cadence monthly Why it matters Indicates pipeline strength and future market expansion for advanced tissue regeneration. Signal to watch Increase in new trials or positive interim results. Confidence: Medium | 1. Adzuna / LinkUp — Job Postings DataMatchedlinkup_job_postings · access=file · map_only Metric/field Job openings for 'BD Advanced Patient Monitoring Sales' or 'BD PureWick Sales' Cadence monthly Why it matters Proxies ongoing commercial investment and expansion in key growth platforms. Signal to watch Consistent or increasing number of sales-related job postings in these specific areas. Confidence: Medium |
| BD Excellence Productivity Gains and AI Deployment | Operational excellence and productivity improvements are crucial for margin expansion, offsetting cost pressures like tariffs, and driving efficiency across the company's supply chain and G&A functions, directly impacting profitability and cash flow. | Reported gross productivity improvements in plants (e.g., maintaining or exceeding 8% quarterly), and updates on the deployment and quantifiable impact of the standardized digital platform for AI in the supply chain and G&A functions. | Bullish if BD continues to report strong gross productivity (e.g., 8% or higher) and provides concrete examples of AI-driven savings or efficiency improvements in supply chain or G&A functions. | Company earnings calls, investor presentations, and annual reports. | [] | 1. Gartner / IDC — Enterprise AI Adoption SurveysMatchedgartner_enterprise_buyer_surveys · access=file · map_only Metric/field AI/ML spending and deployment rates in MedTech manufacturing and supply chain Cadence quarterly/annually Why it matters Benchmarks BD's AI adoption against industry peers, indicating leadership or lag in efficiency innovation. Signal to watch BD's reported AI deployment pace exceeding industry averages. Confidence: Medium |
| Stabilization of Vaccine Demand and China Revenue Contribution | These represent two of the 'less than 10% of portfolio' headwinds. Their stabilization or reduced impact is crucial for mitigating overall revenue drag and improving the predictability of BD's financial performance. | Management commentary on vaccine order patterns and demand stabilization, confirmation of 'lapping the vaccine headwind' in the next quarter, and the actual revenue contribution from China (expected to drop to 3-4% of New BD revenue) in subsequent earnings reports. | Bullish if management confirms sustained stabilization or recovery in vaccine demand, and if China's revenue contribution is reported to be consistently at or below 3% of total New BD revenue, indicating a reduced drag on overall growth. | Company earnings calls, press releases, and investor presentations, particularly during the Q4 2026 and FY27 guidance calls. | [] | 1. Wind Information / CEIC Data — China Healthcare Market DataNot in registry Metric/field Medical device import/export data for BD's product categories in China Cadence monthly Why it matters Provides an external view of BD's market performance and competitive dynamics in China. Signal to watch Stabilization or improvement in BD's product category import/export trends. Confidence: Medium |
| GLP-1 Program Growth and New Agreements | BD's strong position in biologic drug delivery, particularly with GLP-1s, is a key driver of double-digit growth and favorable mix, fueling top and bottom-line performance and expanding its market presence in a high-growth area. | Announcements of new customer agreements for GLP-1 programs exceeding the current 100 agreements, specific product launches utilizing BD's delivery systems (e.g., Vystra pen), and reported double-digit growth rates in the BioPharma Systems biologics segment. | Bullish if BD continues to announce new GLP-1 agreements that significantly exceed 100, launches more high-value delivery systems like the Vystra pen, and maintains double-digit growth in its biologics segment. | Company earnings calls, press releases, investor presentations, and industry conferences. | 1. Google Trends — Search InterestNot in registry Metric/field Search term volume for 'GLP-1 drug delivery' AND 'BD Vystra' Cadence weekly Why it matters Indicates public and pharmaceutical industry interest in BD's GLP-1 related products and delivery systems. Signal to watch Sustained or increasing search interest in BD's GLP-1 solutions. Confidence: Medium | 1. IQVIA / Symphony Health — Pharmaceutical Sales DataMatchediqvia_pharma_sales_channel_data · access=file · map_only Metric/field Sales volume of GLP-1 drugs utilizing BD delivery systems Cadence monthly Why it matters Provides direct insight into the commercial uptake and market penetration of BD's GLP-1 related products. Signal to watch Consistent month-over-month growth in sales volume. Confidence: High |
Key Reported Metrics, Reratings Triggers & ResultsThis segment is a key growth driver, particularly due to GLP-1 programs, reflecting BD's strategic investments in high-growth markets. Excluding vaccine impacts
Upcoming print · 2026-11-05
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| BioPharma Systems (excluding vaccines) Growth | mid-teens | This segment is a key growth driver, particularly due to GLP-1 programs, reflecting BD's strategic investments in high-growth markets. Excluding vaccine impacts provides a clearer view of the underlying strength and future potential of this critical platform. | Reported growth of 15% or higher. | This segment, particularly biologics/GLP-1s, is a key high-growth driver for BD's 'New BD' strategy. Sustained double-digit growth here demonstrates successful innovation and commercial execution, validating the company's strategic focus and contributing to a favorable mix and overall revenue acceleration. | |
| Alaris Headwind Impact on Total Revenue | 100 bps headwind | The Alaris remediation represents a significant, defined headwind impacting overall revenue growth. Monitoring its magnitude in the next quarter is crucial for assessing the underlying performance of the "New BD" and anticipating the eventual acceleration post-remediation. | An impact of less than 200 basis points headwind. | The Alaris remediation is a significant, defined drag on BD's revenue, expected to be a 200 bps headwind in Q4 2026. A smaller-than-expected headwind would signal faster resolution or better mitigation, reducing uncertainty and accelerating the path to BD's mid-single-digit growth algorithm. | |
| Total Revenue (FX-neutral) Growth | 4.4% | This is the primary indicator of BD's top-line performance and commercial momentum following its strategic spin-off. Investors will closely watch if the company can sustain broad-based growth and meet its updated full-year guidance despite anticipated Q4 deceleration. | FX-neutral revenue growth of 3% or higher. | Despite anticipated Q4 deceleration due to Alaris, sustaining strong FX-neutral growth demonstrates robust underlying commercial momentum and execution of the 'New BD' strategy. Exceeding expectations would signal resilience and confidence in achieving long-term growth targets. | |
Key QuestionsWill BD's strong performance in growth platforms and operational efficiencies sufficiently mitigate the anticipated sequential deceleration in Q4 fiscal 2026 an
Will BD's strong performance in growth platforms and operational efficiencies sufficiently mitigate the anticipated sequential deceleration in Q4 fiscal 2026 and the projected 200 basis point Alaris headwind in fiscal 2027 to maintain its updated full-year guidance and initial FY27 outlook?
- Question 2
Can BD sustain the double-digit growth in its key platforms, particularly GLP-1 related biologics and newly launched products like Liverty and Elyra, to drive revenue acceleration beyond the Alaris headwind and capitalize on commercial investments?
- Question 3
To what extent will BD Excellence and the new AI deployment initiatives effectively drive further operational productivity and margin expansion, offsetting persistent tariff impacts, potential inflationary pressures, and the flow-through impact of the Alaris revenue decline?
Earnings Transcript Summary
· 2026Q3 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Compete Strategy**: Advancing commercial excellence with greater customer focus, stronger accountability, and faster decision-making to convert BD's portfolio strength into faster growth, deeper customer partnerships, and sustainable share gains. This includes targeted commercial investments in high-growth areas like Advanced Patient Monitoring (APM), Urology & Critical Care (UCC), and Peripheral Intervention (PI). 2. **Innovate Strategy**: Focusing the pipeline on attractive markets where BD's solutions are most needed, such as connected care, enabling the shift to lower-cost settings, and advancing treatment for specific chronic diseases. This involves increasing the cadence and speed of new product launches. 3. **Deliver Strategy (Operational Excellence)**: Achieving operational excellence at scale through BD Excellence to improve quality, service, productivity, margin, and cash flow. This includes plant consolidations, raw material savings, waste reduction, and the deployment of a standardized digital platform for AI across the supply chain. | Call Takeaway & ToneThe overall takeaway of the call is that BD delivered a strong third fiscal quarter of 2026, exceeding expectations for revenue, adjusted operating margin, and adjusted EPS. The performance was broad-based, driven by strong execution across key growth platforms and the benefits of the 'New BD' strategy focusing on commercial excellence, innovation, and operational efficiency through BD Excellence. Management expressed confidence in continued momentum and raised full-year guidance. The tone of the call was positive and confident, with management emphasizing the strategic pillars and their ability to mitigate known headwinds like Alaris, China, and vaccine demand. | Prior Quarter'S Y/Y Growth By SegmentMedical Essentials: 1.7% growth; Connected Care: 3.3% growth; BioPharma Systems: declined 1.8%; Interventional: 5.3% growth; MMS (within Connected Care): 0.4% growth. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Strength in Q3 Performance and FY27 Outlook**: Analysts questioned the broad-based strength in Q3, potential one-time factors, and how this momentum carries into FY27, especially regarding revenue guidance. Management responded that the strong growth was broad-based, driven by momentum in their growth platforms (many growing double-digits or high single-digits), and that they continue to invest commercially and in innovation, which also provides favorable mix benefits. For FY27, management indicated a low single-digit revenue growth framework due to a 200 basis point Alaris headwind, but expected modest EPS leverage supported by pricing actions, productivity, and capital allocation. 2. **Headwinds from the 10% of the Portfolio (Alaris, China, Vaccines)**: Analysts inquired about the trends, visibility on these headwinds ending, and other dragging line items. Management clarified that all three headwinds were playing out as expected. They noted positive signs of stabilization in vaccines, expecting to lap the headwind next quarter with preliminary order patterns not showing a repeat in FY27. China is a smaller portion of New BD's revenue (4%, likely dropping to 3%), and while a dynamic environment is assumed, its impact will be less significant. Alaris is a defined headwind (100 bps in FY26, 200 bps in FY27) that will cease thereafter. 3. **Long-Term Operating Margin Expansion and Alaris Impact on Margins**: Analysts pressed on the potential for further productivity enhancements, efficiency, and portfolio changes to drive operating margin expansion towards the end of the decade, and how the Alaris revenue headwind would impact margins. Management highlighted continued focus on revenue growth, positive mix benefits from growth platforms, and ongoing momentum from BD Excellence (8% productivity improvements quarterly). They also mentioned new initiatives like AI deployment for supply chain efficiency and G&A function improvements. While not providing a specific long-term target, they stated that Q4 margins would see enhancements despite the Alaris pressure, due to productivity gains, and that pricing actions, favorable mix, and BD Excellence would mitigate the natural drop-through of Alaris revenue decline in FY27. | Revenue SegmentsMedical Essentials: 3.2% growth; Connected Care: 4.4% growth; BioPharma Systems: 5.2% growth (mid-teens excluding vaccines); Interventional: 5.5% growth; MMS (within Connected Care): low single-digit growth. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketBD expanded its vascular portfolio with the early European launch of the Liverty TIPS Stent Graft, entering a market that has seen limited innovation for many years and broadening BD's presence in the approximately $2 billion global venous market. The company also launched the Elyra Thulium Fiber Laser System, expanding its kidney stone portfolio and presence in the approximately $1.5 billion endourology market. Additionally, BD is expanding its noninvasive monitoring portfolio in APM with the Acumen IQ Plus Finger Cuff and Smart Pressure Controller, aiming to reach underserved OR and ICU patients. The company is in early stages of reimbursement for at-home PureWick, which is seen as an exciting future growth vector. BD has signed approximately 100 agreements across novel and biosimilar GLP-1 programs, including a new collaboration with EMS in Brazil for a semaglutide therapy utilizing the Vystra injection pen. | About CompetitionBD reported continued share gains in Alaris this quarter, up over 200 basis points year-to-date, and strong U.S. performance in MDS and specimen management driven by share gains. In specimen management, high single-digit growth was achieved through share gains across the BD Vacutainer portfolio, improved supply, and capitalizing on competitor back orders. The company is achieving high win rates across the biologics market, including GLP-1s. BD's scale, combined with BD Excellence embedded across its manufacturing network, is considered a growing competitive advantage. | About The Broader IndustryBD observes that healthcare is undergoing a significant transformation, becoming more connected, automated, and personalized. The company noted solid hospital utilization across its portfolio, reflected in strong U.S. MDS growth. An internal metric tracking the ratio of tubes sold to needles sold indicates an uptick in tube utilization versus needle utilization over the last couple of quarters, suggesting more diagnostic testing per patient. This trend could be due to higher acuity patients or new innovative cancer screening. The endourology market, valued at approximately $1.5 billion, is increasingly driven by disposables. | Where Things Are HeadedBD is updating its full-year guidance, now expecting revenue growth toward the high end of its low single-digit range and raising the midpoint of its adjusted EPS guidance. The company anticipates revenue growth to be toward the high end of its low single-digit FX-neutral range for fiscal '26, with currency expected to be a tailwind of about 100 basis points. Adjusted operating margin is expected to remain around 25%, inclusive of tariff impacts, and adjusted EPS guidance is updated to $12.62 to $12.72. For fiscal '27, BD expects low single-digit revenue growth, factoring in a 200 basis point headwind from the Alaris remediation ending in fiscal '26. The company anticipates modest EPS leverage in FY '27, supported by pricing actions, BD Excellence productivity gains, and capital allocation strategy. BD plans to continue investing in commercial and innovation to fuel growth for '28 and beyond. The company is seeing positive stabilization in vaccine demand and expects China's revenue contribution to drop to 3-4% of New BD revenue next year. BD will host an Investor Day soon to share more long-term targets. Future product drivers are expected in growth platforms like APM (including connecting APM monitoring and Alaris pumps), tissue regeneration (with new clinical trials), pharmacy automation, biologics (GLP-1s and novel biologics), Connected Care (Pyxis Pro, BD Incada), and PureWick (new products and reimbursement efforts for at-home use). | Updates On ThemeDiagnostics | Broader Themes EmergingThe deep integration of AI and machine learning is evolving beyond data analysis to directly influence assay development, computational pathology, and personalized treatment pathways. BD is investing in a standardized digital platform to run AI across its end-to-end supply chain for productivity and service improvement. AI is also being deployed to sales teams to enhance account visits and targeting. The company also mentioned a new AI platform, BD Incada. | Bullish-Leaning Quotes (Short)We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. Performance was broad-based, reflecting commercial momentum across our key growth platforms. More than 90% of the portfolio delivering high single-digit growth. We're winning more consistently, scaling our growth platforms faster and strengthening our position with customers around the world. We're up to 100 deals in the GLP-1 space. | Bearish-Leaning Quotes (Short)Growth was partially offset by known dynamics concentrated in less than 10% of our portfolio, primarily the difficult prior year comparison in Alaris as well as vaccines in China. Margins... were offset by approximately 110 basis points of tariff impact. Alaris remediation... creates a 200 basis points headwind next year. China is a much smaller portion of BD... going to probably drop into the 3s as the rest of the BD is growing faster. | HiringBD appointed Mike Feld as its first-ever Chief Revenue Officer. The company reallocated commercial headcount into high-growth spaces, making a $35 million incremental investment. This included growing the APM sales team by about 15% in the U.S., adding more sales headcount in UCC, and establishing a dedicated sales team for the VA channel for PureWick. The PI sales team also grew by 15% in the U.S. Mike Garrison, EVP and President of Medical Essentials and BioPharma Systems, announced his retirement, and Peter Menziuso joined as EVP and President of BD Interventional. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketBD expanded its vascular portfolio with the early European launch of the Liverty TIPS Stent Graft, entering a market that has seen limited innovation for many years and broadening BD's presence in the approximately $2 billion global venous market. The company also launched the Elyra Thulium Fiber Laser System, expanding its kidney stone portfolio and presence in the approximately $1.5 billion endourology market. Additionally, BD is expanding its noninvasive monitoring portfolio in APM with the Acumen IQ Plus Finger Cuff and Smart Pressure Controller, aiming to reach underserved OR and ICU patients. BD has signed approximately 100 agreements across novel and biosimilar GLP-1 programs, including a new collaboration with EMS in Brazil for a semaglutide therapy utilizing the Vystra injection pen. The company is in early stages of reimbursement for at-home PureWick, which is seen as an exciting future growth vector. | About CompetitionBD reported continued share gains in Alaris this quarter, up over 200 basis points year-to-date. Strong U.S. performance in MDS and specimen management was driven by broad underlying utilization as well as share gains. In specimen management, high single-digit growth was achieved through share gains across the BD Vacutainer portfolio, improved supply, and capitalizing on competitor back orders. The company is achieving high win rates across the biologics market, including GLP-1s. BD's scale, combined with BD Excellence embedded across its manufacturing network, is considered a growing competitive advantage. | About The Broader IndustryBD observes that healthcare is undergoing a significant transformation, becoming more connected, automated, and personalized. The company noted solid hospital utilization across its portfolio, reflected in strong U.S. MDS growth. An internal metric tracking the ratio of tubes sold to needles sold indicates an uptick in tube utilization versus needle utilization over the last couple of quarters, suggesting more diagnostic testing per patient. This trend could be due to higher acuity patients or new innovative cancer screening. The endourology market, valued at approximately $1.5 billion, is increasingly driven by disposables. | Where Things Are HeadedBD is updating its full-year guidance, now expecting revenue growth toward the high end of its low single-digit range and raising the midpoint of its adjusted EPS guidance. For fiscal '26, the company anticipates revenue growth to be toward the high end of its low single-digit FX-neutral range, with currency expected to be a tailwind of about 100 basis points. Adjusted operating margin is expected to remain around 25%, inclusive of tariff impacts, and adjusted EPS guidance is updated to $12.62 to $12.72. For fiscal '27, BD expects low single-digit revenue growth, factoring in a 200 basis point headwind from the Alaris remediation ending in fiscal '26. The company anticipates modest EPS leverage in FY '27, supported by pricing actions, BD Excellence productivity gains, and capital allocation strategy. BD plans to continue investing in commercial and innovation to fuel growth for '28 and beyond. The company is seeing positive stabilization in vaccine demand, with preliminary order patterns not showing a repeat of the current headwind level in '27, and expects China's revenue contribution to drop to 3-4% of New BD revenue next year. BD will host an Investor Day soon to share more long-term targets and unveil innovations, including connecting APM monitoring technology and Alaris pumps. | Updates On ThemeDiagnostics | Broader Themes EmergingAI: BD is investing in the deployment of a standardized digital platform designed to run AI across its end-to-end supply chain for productivity and service improvement. AI is also being deployed to sales teams to enhance account visits and targeting, and the company mentioned a new AI platform, BD Incada. | Bullish-Leaning Quotes (Short)We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. More than 90% of the portfolio delivering high single-digit growth. We're winning more consistently, scaling our growth platforms faster and strengthening our position with customers around the world. We're up to 100 deals in the GLP-1 space. | Bearish-Leaning Quotes (Short)Growth was partially offset by known dynamics concentrated in less than 10% of our portfolio, primarily the difficult prior year comparison in Alaris as well as vaccines in China. Margins... were offset by approximately 110 basis points of tariff impact. Alaris remediation... creates a 200 basis points headwind next year. China is a much smaller portion of BD... going to probably drop into the 3s as the rest of the BD is growing faster. | HiringBD grew the APM sales team by about 15% in the U.S., contributing approximately 100 to 150 basis points to APM's double-digit growth this quarter. A dedicated sales team was put in place to pursue the Veterans Administration opportunity for PureWick. The PI sales team was grown by 15% this year in the U.S. The company recently brought in a new President for the Pharmacy Automation category and a new leader for the GBS organization to drive efficiencies in G&A functions. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-08-06 | Becton, Dickinson and Company (BDX) delivered a strong Q3 2026, surpassing expectations with broad-based growth and raised full-year guidance. Management expressed confidence in mitigating Alaris, China, and vaccine headwinds. The market reacted very positively, with BDX stock returning 3.63% (t+2 days), significantly outperforming SPY's 0.42%, aligning with the company's optimistic outlook. | Earnings Transcript | Neutral | +3.63% (vs SPY: +3.21%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| BDX_96cf314e | forthcoming | 2026-10-25 | 2027-01-25 | BD's Investor Day, where the company plans to unveil innovations connecting APM monitoring technology and Alaris pumps, and new PureWick products. | This event will showcase BD's pipeline in key growth platforms, potentially driving investor sentiment and providing clarity on future revenue drivers and long-term targets. | Ticker | 2026-08-06 | earnings_transcript |